GALVOKIMIG
UNII 85A4592PC8

Substance Identification & Data

This profile provides standardized clinical and technical data for Galvokimig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 85A4592PC8.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2648456-30-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

85A4592PC8

CAS Registry Number

2648456-30-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

GALVOKIMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203147

National Cancer Institute reference terminology for clinical and research data.

INN ID

12378

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-172

Identifier assigned by the United States Adopted Names Council.

Substance Type

Galvokimig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Galvokimig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Galvokimig

Common Names & Synonyms

Fused G1(VH-CH1-h)-scFv heavy-kappa heavy chain humanized (1-492) [VH-IGHG1 CH1-h anti-IL-17A/F humanized (1-228) [VH (Homo sapiens IGHV3-7*01 (88.7%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125)-Homo sapiens IGHG1*01, G1m17 CH1 K120 (CH1 K120 (222) (126-223), hinge 1-5 (224-228)(126-228))] -11-mer (seryl-tetraglycyl-threonyl-tetraglycyl-seryl) linker (229-239) -scFv heavy-kappa anti-ALB humanized, scFv-v1 C49 (VH)-C120 (VL) (240-492) [VH (Homo sapiens IGHV3-23*01 (78.6%) -(IGHD) -IGHJ2*01 (93.3%), C49 (283), CDR-IMGT [8.7.15] (265-272.290-296.335-349)) (240-360) -20-mer tetrakis(tetraglycyl-seryl) linker (361-380) -V-KAPPA (Homo sapiens IGKV1-12*01 (86.5%) -(IGHD) -IGKJ1*01 (90.9%) C120 (483), CDR-IMGT [7.3.11] (407-413.431-433.470-480))(381-492)]], (228-214')-disulfide with the fused L-kappa-scFv heavy-kappa light chain humanized (1'-469') [L-kappa anti-IL-17A/F humanized (1'-215') [V-KAPPA (Homo sapiens IGKV1-13*02 (80.0%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%),Km3, A45.1 (153), V101 (191) (108'-214')] -11-mer seryl-bis(tetraglycyl-seryl) linker (215'-225') -scFv heavy-kappa anti-IL13 humanized, scFv-v1 C49 (VH)-C120 (VL) (226'-469') [VH(Homo sapiens IGHV1-69*08 (81.6%) -(IGHD) -IGHJ1*01 (100%), C49 (269'), CDR-IMGT [8.8.9] (251'-258'.276'-283'.322'-330')) (226'-341') -20-mer tetrakis(tetraglycyl-seryl) linker (342'-361') -V-KAPPA (Homo sapiens IGKV1-NL1*01(83.9%) -(IGHD) -IGKJ2*01 (91.7%), C120 (460'), CDR-IMGT [6.3.8] (388'-393'.411'-413'.450'-457')) (362'-469')]], produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated

GALVOKIMIG [USAN]

Immunoglobulin G1(VH-CH1-h)-scFv_L-kappa-scFv, anti-[Homo sapiens IL17A (interleukin 17A, IL-17A) and IL17F (interleukin 17F, IL-17F)], anti-[Homo sapiens IL13 (interleukin 13, IL-13)], anti-[Homo sapiens ALB (albumin, human serum albumin, HSA], humanized monoclonal antibody, trispecific, trivalent

Immunoglobulin G1, anti-(human interleukin 17A/interleukin 17F) (human-Rattus norvegicus γ1-chain C-terminal fragment) fusion protein with peptide linker (SGGGGTGGGGS) fusion protein with immunoglobulin [283-cysteine,483-cysteine] anti-(human serum al...

galvokimig [INN]